Amylyx Pharmaceuticals, Inc.
AMLX
Kedudukan dalam Saham
#4494
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$27.25
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.42B
Perubahan (1 hari)
3.45%
Perubahan (1 tahun)
77.29%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Pendapatan untuk Amylyx Pharmaceuticals, Inc. (AMLX)
Pendapatan pada Jun 2026 TTM: $-152.05M
Menurut laporan kewangan terkini Amylyx Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-152.05M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $54.30M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-197.60M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Amylyx Pharmaceuticals, Inc. dari 2019 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-152.05M | -49.68% |
| 2024 | $-302.14M | -656.45% |
| 2023 | $54.30M | -127.48% |
| 2022 | $-197.60M | 124.72% |
| 2021 | $-87.93M | 107.97% |
| 2020 | $-42.28M | 208.25% |
| 2019 | $-13.72M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -3,569.28% |
US
|
|
| $-3.09B | 1,930.31% |
US
|
|
| $-4.02B | 2,541.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,382.93% |
NL
|
